Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs), specifically regarding the vesting of conditional share awards granted in 2009 under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data point disclosed is the closing middle market price of an Ordinary share of GlaxoSmithKline plc on February 17, 2012, which was £14.14.
Material Changes
The filing details the outcome of performance-based share awards for three senior executives (Mr. P. Thomson, Dr. P. Vallance, and Mrs. V. Whyte) based on performance targets from January 1, 2009, to December 31, 2011. Key outcomes include:
- EPS Measure: 0% of the EPS portion of the awards vested; the entire EPS portion lapsed for all three executives.
- Operational Measure: Varying portions of the operational awards vested or lapsed depending on the individual executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of share award vesting events in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the specific operational performance targets that allowed partial vesting for Dr. P. Vallance and others, given the total lapse of the EPS portion.
- Confirm the total number of shares vested versus lapsed for each named executive to assess the impact on executive compensation.
- Review the full 2011 annual report for the underlying EPS and operational performance data that triggered these vesting outcomes.